OLD Mutual Customised Solutions Proprietary Ltd. raised its holdings in shares of Teva Pharmaceutical Industries Ltd (NYSE:TEVA) by 179.1% in the second quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 28,988 shares of the company’s stock after buying an additional 18,600 shares during the period. OLD Mutual Customised Solutions Proprietary Ltd.’s holdings in Teva Pharmaceutical Industries were worth $705,000 at the end of the most recent quarter.

A number of other hedge funds have also made changes to their positions in TEVA. Pinnacle Associates Ltd. increased its stake in shares of Teva Pharmaceutical Industries by 11.0% in the second quarter. Pinnacle Associates Ltd. now owns 22,862 shares of the company’s stock worth $556,000 after purchasing an additional 2,272 shares in the last quarter. ARK Investment Management LLC boosted its position in shares of Teva Pharmaceutical Industries by 9.2% during the second quarter. ARK Investment Management LLC now owns 30,487 shares of the company’s stock worth $741,000 after acquiring an additional 2,561 shares during the last quarter. Point View Wealth Management Inc. boosted its position in shares of Teva Pharmaceutical Industries by 4.4% during the second quarter. Point View Wealth Management Inc. now owns 71,603 shares of the company’s stock worth $1,741,000 after acquiring an additional 2,996 shares during the last quarter. Cornerstone Investment Partners LLC boosted its position in shares of Teva Pharmaceutical Industries by 19.6% during the second quarter. Cornerstone Investment Partners LLC now owns 18,300 shares of the company’s stock worth $445,000 after acquiring an additional 3,000 shares during the last quarter. Finally, IFM Investors Pty Ltd boosted its position in shares of Teva Pharmaceutical Industries by 12.2% during the first quarter. IFM Investors Pty Ltd now owns 28,340 shares of the company’s stock worth $484,000 after acquiring an additional 3,089 shares during the last quarter. 64.52% of the stock is owned by institutional investors and hedge funds.

A number of brokerages recently weighed in on TEVA. Cantor Fitzgerald set a $25.00 target price on shares of Teva Pharmaceutical Industries and gave the stock a “hold” rating in a research report on Friday. Credit Suisse Group lowered shares of Teva Pharmaceutical Industries from an “outperform” rating to a “neutral” rating and dropped their target price for the stock from $25.00 to $23.00 in a research report on Friday, September 7th. Mizuho restated a “buy” rating and set a $28.00 target price on shares of Teva Pharmaceutical Industries in a research report on Friday, August 24th. ValuEngine upgraded shares of Teva Pharmaceutical Industries from a “hold” rating to a “buy” rating in a research report on Tuesday, August 7th. Finally, Barclays set a $23.00 target price on shares of Teva Pharmaceutical Industries and gave the stock a “hold” rating in a research report on Thursday, August 2nd. Eight analysts have rated the stock with a sell rating, fifteen have given a hold rating and seven have given a buy rating to the company’s stock. Teva Pharmaceutical Industries currently has an average rating of “Hold” and a consensus target price of $20.91.

TEVA stock opened at $22.85 on Friday. Teva Pharmaceutical Industries Ltd has a 52 week low of $10.85 and a 52 week high of $25.96. The company has a debt-to-equity ratio of 1.86, a current ratio of 1.03 and a quick ratio of 0.69. The firm has a market cap of $22.57 billion, a price-to-earnings ratio of 6.31, a price-to-earnings-growth ratio of 2.77 and a beta of 0.69.

Teva Pharmaceutical Industries (NYSE:TEVA) last released its quarterly earnings data on Thursday, August 2nd. The company reported $0.78 EPS for the quarter, beating the Thomson Reuters’ consensus estimate of $0.64 by $0.14. Teva Pharmaceutical Industries had a negative net margin of 47.98% and a positive return on equity of 19.92%. The business had revenue of $4.70 billion during the quarter, compared to analyst estimates of $4.75 billion. During the same quarter last year, the business earned $1.02 earnings per share. Teva Pharmaceutical Industries’s quarterly revenue was down 17.8% compared to the same quarter last year. research analysts anticipate that Teva Pharmaceutical Industries Ltd will post 2.67 EPS for the current fiscal year.

In other news, EVP Sven Dethlefs bought 2,000 shares of the stock in a transaction dated Friday, August 3rd. The stock was purchased at an average price of $21.92 per share, for a total transaction of $43,840.00. Following the acquisition, the executive vice president now owns 6,445 shares of the company’s stock, valued at $141,274.40. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Also, EVP Iris Beck Codner sold 4,165 shares of the firm’s stock in a transaction dated Thursday, August 9th. The stock was sold at an average price of $22.70, for a total transaction of $94,545.50. Following the completion of the sale, the executive vice president now owns 8,290 shares of the company’s stock, valued at approximately $188,183. The disclosure for this sale can be found here. 0.43% of the stock is currently owned by company insiders.

Teva Pharmaceutical Industries Company Profile

Teva Pharmaceutical Industries Limited, a pharmaceutical company, develops, manufactures, markets, and distributes generic medicines and a portfolio of specialty medicines worldwide. It operates through two segments, Generic Medicines and Specialty Medicines. The Generic Medicines segment offers sterile products, hormones, narcotics, high-potency drugs, and cytotoxic substances in various dosage forms, including tablets, capsules, injectables, inhalants, liquids, ointments, and creams.

Further Reading: How are Outstanding Shares Different from Authorized Shares?

Want to see what other hedge funds are holding TEVA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Teva Pharmaceutical Industries Ltd (NYSE:TEVA).

Institutional Ownership by Quarter for Teva Pharmaceutical Industries (NYSE:TEVA)

Receive News & Ratings for Teva Pharmaceutical Industries Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Teva Pharmaceutical Industries and related companies with MarketBeat.com's FREE daily email newsletter.